[
  {
    "ts": "2026-01-31T05:09:15+00:00",
    "headline": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
    "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
    "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "34ccbb37-ccd1-3311-938d-2172535f701e",
      "content": {
        "id": "34ccbb37-ccd1-3311-938d-2172535f701e",
        "contentType": "STORY",
        "title": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
        "pubDate": "2026-01-31T05:09:15Z",
        "displayTime": "2026-01-31T05:09:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T12:49:28+00:00",
    "headline": "Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a […]",
    "url": "https://finance.yahoo.com/news/cantor-fitzgerald-raises-pfizer-pfe-124928756.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "fec0dceb-4255-3df4-b4ea-df55a51999ce",
      "content": {
        "id": "fec0dceb-4255-3df4-b4ea-df55a51999ce",
        "contentType": "STORY",
        "title": "Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to invest in now. On January 27, Cantor Fitzgerald raised the firm’s price target on Pfizer to $27 from $24 and maintained a Neutral rating on the shares. With 2026 guidance already established and only modest beat-and-raise potential anticipated, the firm expects a […]",
        "pubDate": "2026-01-31T12:49:28Z",
        "displayTime": "2026-01-31T12:49:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4d0e18df3bfe296b60430f61e3300cd3",
          "originalWidth": 750,
          "originalHeight": 497,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9XLcyjlF8WDR7TcdO1LqvQ--~B/aD00OTc7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4d0e18df3bfe296b60430f61e3300cd3.cf.webp",
              "width": 750,
              "height": 497,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b2Nk8AlNstLLW.0dtGLIcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4d0e18df3bfe296b60430f61e3300cd3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-raises-pfizer-pfe-124928756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cantor-fitzgerald-raises-pfizer-pfe-124928756.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T12:58:18+00:00",
    "headline": "BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets",
    "summary": "We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement […]",
    "url": "https://finance.yahoo.com/news/bofa-notes-positive-interest-novavax-125818403.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "18d3fa8c-aa70-3ff5-a5d5-2e434998deaf",
      "content": {
        "id": "18d3fa8c-aa70-3ff5-a5d5-2e434998deaf",
        "contentType": "STORY",
        "title": "BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets",
        "description": "",
        "summary": "We recently compiled a list of the 9 High Growth Small Cap Stocks That Are Profitable. Novavax, Inc. stands second on our list of high growth stocks. TheFly reported on January 20 that BofA raised its price target on NVAX to $7 from $6 while maintaining an Underperform rating. The update followed the company’s announcement […]",
        "pubDate": "2026-01-31T12:58:18Z",
        "displayTime": "2026-01-31T12:58:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4b9ae3e820991409356264f5ee1180f1",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uyj2Rz57RH_ntM0L06zAjQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/4b9ae3e820991409356264f5ee1180f1.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TwFme34d1nKxga1zEuJT5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4b9ae3e820991409356264f5ee1180f1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-notes-positive-interest-novavax-125818403.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-notes-positive-interest-novavax-125818403.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-31T11:43:00+00:00",
    "headline": "Pfizer CEO Albert Bourla’s best leadership advice: Being optimistic is better than being right",
    "summary": "Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.",
    "url": "https://finance.yahoo.com/news/pfizer-ceo-albert-bourla-best-114300302.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "4cfa9d9d-cba5-3aae-9811-da058f49a429",
      "content": {
        "id": "4cfa9d9d-cba5-3aae-9811-da058f49a429",
        "contentType": "STORY",
        "title": "Pfizer CEO Albert Bourla’s best leadership advice: Being optimistic is better than being right",
        "description": "",
        "summary": "Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.",
        "pubDate": "2026-01-31T11:43:00Z",
        "displayTime": "2026-01-31T11:43:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/ce7a90928ec86796568d6adc15ae5aaf",
          "originalWidth": 2048,
          "originalHeight": 1365,
          "caption": "Albert Bourla, the boss of the $150 billion pharmaceutical giant Pfizer, admits leaders don’t win by always being right—the key is being someone your peers want to follow.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qDQq7_jqh99Kzj4fKO8jHg--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/ce7a90928ec86796568d6adc15ae5aaf.cf.webp",
              "width": 2048,
              "height": 1365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/feXVBNOXCugLpN3_7mDyKg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/ce7a90928ec86796568d6adc15ae5aaf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ceo-albert-bourla-best-114300302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ceo-albert-bourla-best-114300302.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]